1	Heterogeneity of the Effect of Telemedicine Hypertension Management Approach
2	on Blood Pressure: A Systematic Review and Meta-analysis of US-based Clinical
3	Trials
4	
5	Sameer Acharya, ¹ MD; Gagan Neupane, ² MD; Austin Seals, ³ MS; Madhav KC ⁴ , PhD,
6	MPH; Dean Giustini, ⁵ MLS, MEd; Sharan Sharma, ⁶ MD; Yhenneko J. Taylor, ⁷ PhD;
7	Deepak Palakshappa, ⁸ MD, MSHP; Jeff D. Williamson, ⁹ MD, MHS; Justin B. Moore, ¹⁰
8	PhD, MS; Hayden B. Bosworth, ¹¹ PhD; Yashashwi Pokharel, ³ MD, MSCR.
9	
10	¹ Department of Internal Medicine, Cayuga Medical Center, Ithaca, New York, USA.
11	² Department of Internal Medicine, Florida Atlantic University, Boca Raton, Florida, USA.
12	³ Section of Cardiovascular Medicine, Department of Internal Medicine, Atrium Health
13	Wake Forest Baptist, Winston-Salem, North Carolina, USA.
14	⁴ Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale
15	School of Medicine, New Haven, Connecticut, USA.
16	⁵ University of British Columbia, Vancouver, British Columbia, Canada
17	⁶ SCL Heart and Vascular Institute, Brighton, Colorado, USA.
18	⁷ Center for Outcomes Research and Evaluation, Atrium Health, Charlotte, North
19	Carolina, USA.

- ⁸Department of Internal Medicine, Atrium Health Wake Forest Baptist, Winston-Salem,
- 21 North Carolina, USA.
- ⁹Section of Gerontology and Geriatric Medicine, Department of Internal Medicine,
- Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, USA.
- ¹⁰Department of Implementation Science, Wake Forest University School of Medicine,
- 25 Winston-Salem, North Carolina, USA.
- ²⁶ ¹¹Department of Population Health Sciences, Duke University, Durham, North Carolina,
- 27 USA.

28

- 29 Subtitle
- 30 Informing TM-HTN Implementation in the US

- 32 Corresponding Author:
- 33 Yashashwi Pokharel, MD, MSCR
- 34 Section of Cardiovascular Medicine, Department of Internal Medicine
- 35 Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine
- 36 Medical Center Boulevard, Winston Salem, NC 27157
- 37 Email: <u>ypokhare@wakehealth.edu</u>
- 38 Phone: 336-713-7085, Fax: 336-716-9188

39

40 Abstract word count: 348/350

- 41 Manuscript word count: 4212/5000
- 42

43 Abstract

Background: Telemedicine management of hypertension (TM-HTN) uses home blood
 pressure (BP) to guide pharmacotherapy and telemedicine-based self-management

support (SMS). Optimal approach to implementing TM-HTN in the US is unknown.

47 Methods

48 We conducted a systematic review and a meta-analysis to examine the effect of TM-HTN vs. usual clinic-based care on BP and assessed heterogeneity by patient- and 49 clinician-related factors. We searched US-based randomized clinical trials among adults 50 51 from Medline, Embase, CENTRAL, CINAHL, PsycInfo, and Compendex, Web of Science Core Collection, Scopus, and two trial registries to 7/7/2023. Two authors 52 extracted, and a third author confirmed data. We used trial-level differences in systolic 53 BP (SBP), diastolic BP (DBP) and BP control rate at ≥ 6 months using random-effects 54 models. We examined heterogeneity of effect in univariable meta-regression and in pre-55 56 specified subgroups [clinicians leading pharmacotherapy (physician vs. non-physician). SMS (pharmacist vs. nurse), White vs. non-White patient predominant trials (>50% 57 patients/trial), diabetes predominant trials ($\geq 25\%$ patients/trial) and in trials that have 58

59 majority of both non-White patients and patients with diabetes vs. White patient

60 predominant but not diabetes predominant trials.

61	Results : Thirteen, 11 and 7 trials were eligible for SBP, DBP and BP control,
62	respectively. Differences in SBP, DBP and BP control rate were -7.3 mmHg (95% CI: -
63	9.4, -5.2), -2.7 mmHg (-4.0, -1.5) and 10.1% (0.4%, 19.9%), respectively, favoring TM-
64	HTN. More BP reduction occurred in trials with non-physician vs. physician led
65	pharmacotherapy (9.3/4.0 mmHg vs. 4.9/1.1 mmHg, P<0.01 for both SBP/DBP),
66	pharmacist vs. nurses provided SMS (9.3/4.1 mmHg vs. 5.6/1.0 mmHg, P=0.01 for
67	SBP, P<0.01 for DBP), and White vs. non-White patient predominant trials (9.3/4.0
68	mmHg vs. 4.4/1.1 mmHg, P<0.01 for both SBP/DBP), with no difference by diabetes
69	predominant trials. Lower BP reduction occurred in both diabetes and non-White patient
70	predominant trials vs. White patient predominant but not diabetes predominant trials
71	(4.5/0.9 mmHg vs. 9.5/4.2 mmHg, P<0.01 for both SBP/DBP).

72

73 Conclusions

TM-HTN is more effective than clinic-based care in the US, particularly when nonphysician led pharmacotherapy and pharmacist provided SMS. Non-White patient
predominant trials seemed to achieve lesser BP reduction. Equity conscious, locally
informed adaptation of TM-HTN is needed before wider implementation.

78

80 Clinical Perspective

81 What Is New?

82	٠	In this systematic review and meta-analysis of US-based clinical trials, we found
83		that telemedicine management of hypertension (TM-HTN) was more effective in
84		reducing and controlling blood pressure (BP) compared with clinic based
85		hypertension (HTN) care.
86	•	The BP reduction was more evident when pharmacotherapy was led by non-
87		physician compared with physicians and HTN self-management support was
88		provided by clinical pharmacists compared with nurses,
89	•	Non-White patient predominant trials achieved lesser BP reductions than White
90		patient predominant trials.
91	What	Are the Clinical Implications?
92	•	Before wider implementation of TM-HTN intervention in the US, locally informed
93		adaptation, such as optimizing the team-based HTN care approach, can provide
94		more effective BP control.
95	•	Without equity focused tailoring, TM-HTN intervention implemented as such can
96		exacerbate inequities in BP control among non-White patients in the US.
97		
98		
99		

100 Introduction

Approximately 47% of American adults have hypertension (HTN) but only a quarter of 101 them achieve blood pressure (BP) control, with worse control among non-Hispanic 102 Black or Hispanic adults than White Americans.¹ Managing HTN using traditional clinic-103 based model has several challenges.² Assessment of BP during brief visits are often 104 inaccurate.³ To confidently assess accurate BP control in clinic, it may require up to 5-6 105 BP measurements,⁴ which is not realistic in routine practice. Self-measurement of BP by 106 patients offers more BP data and improves clinicians' confidence about accuracy in BP 107 control.^{5,6} Furthermore, enhancing patients' HTN self-care skills is important,⁷ which is 108 often difficult within the scope of a typical clinic visit. Telemedicine management of 109 hypertension (TM-HTN) employs a focused team-based approach, where 110 pharmacotherapy is based on self-measured BP (SMBP). Ideally, SMBP is transmitted 111 112 using a telemonitoring platform, and self-management support (SMS) is offered via telemedicine.² While TM-HTN has the promise to overcome the challenges of clinic-113 based HTN care, understanding how patient and clinician-related factors influence TM-114 HTN's effect on BP is important. 115

Prior meta-analyses including data outside the US have shown that SMBP with additional support can improve BP.⁸⁻¹⁰ The additional support included heterogeneous levels of SMS with or without SMBP-guided pharmacotherapy. SMBP-guided pharmacotherapy is the essential core of TM-HTN. To our knowledge, we are not aware of any meta-analysis limited to SMBP-guided pharmacotherapy. Accordingly, we conducted a systematic review and meta-analysis of US-based trials that used SMBP-

guided pharmacotherapy. Local US-based data is particularly relevant to inform TM-122 HTN implementation because of the global differences in health care systems and 123 practices. Little is known whether patient and clinician-related factors in the US 124 influence TM-HTN's effect on BP. Generally, BP control is better when medication 125 prescription for HTN is led by non-physicians than by physicians,^{11,12} but it is unknown 126 whether such heterogeneity exists with TM-HTN. Previous meta-analyses have 127 examined the effect of various implementation strategies on BP, with team-based 128 approach having the highest impact. This approach involves task shifting or sharing 129 responsibilities to non-physicians like pharmacists and nurses.¹¹⁻¹³ As a team-based 130 approach in TM-HTN, either physicians or non-physicians could deliver SMBP-guided 131 pharmacotherapy.² It is unknown whether BP achieved in a TM-HTN program varies 132 133 when the pharmacotherapy is led by physicians vs. non-physicians, or when SMS is provided by different clinicians. Similarly, whether TM-HTN's effect varies by patient 134 characteristics is unknown. For example, although Black and non-Black patients derive 135 similar benefits from BP control,¹⁴ there is a persistent disparity in BP control in Black 136 compared with White patients.¹ Therefore, implementing TM-HTN without purposeful 137 equity-conscious delivery plan has the risk of exacerbating inequities in BP control. 138 Accordingly, using a systematic review and meta-analysis of US-based clinical trials of 139 TM-HTN, we examined the effect of TM-HTN vs. usual care on difference in systolic BP 140 141 (SBP), diastolic BP (DBP) and BP control rate and the heterogeneity of TM-HTN's effect by various patient and clinician characteristics. 142

143

145 Methods

146 We registered our study protocol on PROSPERO (CRD42022324076) and Open

147 Science Framework.¹⁵

148 Data Sources and Searches

Together with an academic health sciences librarian, we developed and used a search 149 strategy in six bibliographic databases till July 7, 2023 [Medline (Ovid), Embase (Ovid), 150 CENTRAL (Ovid), CINAHL (Ebsco), PsycInfo (Ebsco), and Compendex]; two citation 151 indexes (Web of Science Core Collection and Scopus) and trial registries 152 (ClinicalTrials.Gov and International Clinical Trials Registry Platform). Several 153 definitions of telemedicine informed our searches.^{2,16,17} We examined broader 154 telemedicine and telehealth terminologies, without limits or exclusions, used in the 155 156 remote monitoring of HTN and BP (Supplement Table 1). We created a list of search terms using exploratory searches and key seed papers, to fit the review's scope:¹⁸ 157 telemedicine and telehealth strategies (e.g., mobile health, telehealth, telemonitoring, 158 159 telemedicine, mHealth, eHealth, videoconferencing, smartphones, virtual care, remote monitoring, health information technology) combined with home BP monitoring (SMBP, 160 home BP measurement, ambulatory BP) and United States-related geographic filter.¹⁹ 161 162 We limited our searches to randomized controlled trials. We obtained a peer review of the Medline search strategy from an information specialist from Cochrane HTN. 163

164 Trial Selection

The essential trial selection required that the clinical trial be US-based, intervention
 used SMBP-guided pharmacotherapy, and SMS was optional. Trials that used SMBP

167 without SMBP-guided pharmacotherapy were excluded. Usual care group used clinic-

based HTN management without a telemedicine program where pharmacotherapy was

not guided by SMBP. Other eligibility criteria are available in the study protocol.

170 Data Extraction and Quality Assessment

171 We saved search results in EndNote, removed duplicate references and transferred the

172 citations into Covidence. Two reviewers (S.A and G.N) independently performed title,

abstract, and full-text screening and data abstraction. A third reviewer (Y.P) resolved

any disagreements and confirmed trials eligibility and data.

When there were more than one comparison arms present in a trial, we used the data from the arm with the most intense intervention as appropriate to our research question. For example, with three arms, 1) usual care, 2) SMBP, and 3) SMBP plus SMS we presented the results for the comparison between 1) usual care, and 3) SMBP plus SMS.

We collected trial level data on patient's mean age, sex, race, education, 180 baseline SBP and DBP, clinicians leading pharmacotherapy and SMS, trial publication 181 year and TM-HTN intervention duration. We found that the clinicians leading 182 pharmacotherapy were either physicians, pharmacists or nurses. Similarly, the clinicians 183 providing SMS were either pharmacists or nurses. We further defined clinicians leading 184 pharmacotherapy (physicians vs. non-physicians) and SMS (pharmacists vs. nurses). If 185 186 a non-physician (e.g., pharmacist) prescribed anti-hypertensive medications without routine and direct approval by physician, then we considered the pharmacotherapy to 187 be led by the pharmacist.¹² Conversely, if the pharmacist prescribed the medications but 188

189	required routine and direct approval by physician, we considered the pharmacotherapy
190	to be led by physician. We defined White vs. non-White patient predominant trials
191	(>50% White or non-White patients per trial) and diabetes predominant trials (\geq 25% vs.
192	<25% of participants with diabetes per trial).

Two authors (M.K. and Y.P.) independently assessed the quality of included trials using the Cochrane risk of bias (RoB) tool version 6.3 and resolved any differences by consensus.²⁰ Two authors (M.K. and Y.P.) independently assessed the strength of evidence using the AHRQ criteria and resolved any differences by consensus.²¹ Supplement Table 2 shows PRISMA checklist.

Data Synthesis and Statistical Analysis

Our outcomes of interest were difference in SBP, DBP and trial defined BP control rate 199 between TM-HTN and usual clinic-based care at ≥ 6 months of the intervention.¹⁴ If 200 multiple BP data were reported within a trial, we used the data for which the sample size 201 was powered for. For example, if the trial provided BP data at 6, 12 and 18 months, but 202 the trial was powered for 12-month BP data, we considered 12-month data for our 203 analysis. We used random effects models, with Hartung-Knapp adjustment for between 204 205 study heterogeneity, to examine the difference in BP outcomes between intervention and usual care. Throughout the study design, we ensured randomized comparisons 206 between TM-HTN and usual care as conducted in individual trials. We calculated 207 standard errors for each trial's effect size from the reported confidence intervals or P-208 value. We conducted analyses in R (4.0.2) using the packages "meta", "metafor" and 209 "dmetar". We considered two-sided P value <0.05 to be statistically significant and did 210

not adjust for multiple comparisons. We quantified between-study heterogeneity using l^2 statistic. We used a comparison-adjusted funnel plot with Egger's test to assess for publication bias. We performed leave one out analysis to estimate the influence of each trial on the pooled effect.

We first examined the association of several patient and clinician-related 215 216 variables with SBP and DBP difference in univariable meta-regression. These variables include patients' mean age, sex (percentage of women/trial), race (White vs. non-White 217 patient predominant trials), education (percentage of participants/trial with \leq high school 218 education), baseline SBP or DBP, diabetes (diabetes patient predominant trials), 219 clinicians leading pharmacotherapy (physicians vs. non-physicians) and SMS 220 (pharmacists vs. nurses) and TM-HTN intervention duration. If there was a significant 221 association for any of these variables, we considered sub-group analysis. As defined 222 priori, we also performed sub-group analyses based on the clinician leading 223 224 pharmacotherapy and SMS, White vs. non-White patient predominant trials, diabetes 225 predominant vs. non-dominant trials and in trials that have majority of both non-White patients and patients with diabetes vs. White patient predominant but not diabetes 226 227 predominant trials.

We identified trials with well-developed SMS focused on enhancing patient's selfcare skills. Such trials required that SMS was tailored for individual patients plus had a considerable emphasis on SMS assessed by frequency, content, and duration of contact.²² We further noted home BP data was transferred to clinics or investigators either by mail or telemonitoring device. To provide insights into using contemporary TM-

HTN programs, in sensitivity analysis, we repeated analysis limiting to trials that usedtelemonitoring for SMBP.

235

236 **Results**

237 Trial Characteristics

We identified 13 eligible trials for SBP, 11 trials for DBP, and 7 trials for BP control, published between 1992-2019 in the US, with 5,330, 4,243 and 3766 participants,

respectively (Figure 1).²³⁻³⁵ Two trials had cluster randomized design^{23,28} and others

randomized individual participants (Table 1). TM-HTN intervention was leveraged via

community in two trials, where patients' physicians used SMBP to guide

pharmacotherapy.^{23,30} Usual care in all trials comprised clinic-based HTN management

with options for 1-2 pharmacist visits in one trial,²⁸ and text-messaging encouraging

lifestyle change in another trial.³⁴ Supplement Tables 3-4 provide additional information

about trials' eligibility, intervention, procedures, and outcomes. Across all trials, mean

247 (SD) age was 60.2 (5.4) years, 47.5% (21.9) were women, 38.2% (23.5) had ≤high

school education, baseline SBP and DBP were 147.4 (8.6) mmHg and 86.6 (3.5)

249 mmHg, respectively. The proportion of non-White patients ranged from 4-100% per trial.

250 Seven were non-White patient predominant trials (four had >50% and other two trials

had 39-48% Black participants/trial; one trial was exclusively in Hispanic adults).

252 Similarly, the proportion of patients with diabetes per trial ranged from 14-100%, and

eight were diabetes patient predominant trials (five were both non-White and diabetes

254 patient predominant trials; three were both White and diabetes patient predominant

trials). None of the non-White patient predominant trials had pharmacotherapy led by

256 non-physicians or SMS provided by pharmacists. Seven trials had well-developed SMS and nine trials used telemonitoring of SMBP (four trials asked patients to mail home BP 257 log) (Table 1 and Supplement Table 4). Well-developed SMS was present in two White 258 and five non-White patient predominant trials, respectively. 259

Three trials (published between 1992-2007) had "some concerns" in RoB 260 assessment from lack of pre-specified protocols.^{29,30,33} One trial had high RoB from 261 large missing outcome data (31.2%).²³ Others had low RoB (Supplement Figure 1). We 262 did not find publication bias (Egger test P=0.83 and 0.26 for SBP and DBP, respectively, 263 Supplement Figure 2). The l^2 statistic was 53% (P=0.01) and 70% (P<0.01) for SBP and 264 DBP, respectively, suggesting some heterogeneity among trials.³⁶ Magid et al. 2013, 265 Soghikian et al, and Artinian et al contributed the most to the heterogeneity in BP 266 difference (Supplement Figure 3). We found high strength of evidence for both SBP and 267 DBP difference (Supplement Table 5).

269

268

270 **BP Outcomes**

The pooled SBP difference was -7.3 mmHg (95% CI: -9.4, -5.2), favoring TM-HTN 271 272 intervention (Figure 2). In univariable meta-regression, the only variables significantly associated with SBP difference were clinicians leading pharmacotherapy and race. SBP 273 reduction was 4.4 mmHg more when pharmacotherapy was led by non-physicians vs. 274 physicians (P<0.01). For every 10% more non-White patients per trial, SBP difference 275 achieved was 0.6 mmHg lower (P=0.03) or 5.0 mmHg lower SBP reduction in non-276 277 White vs. White patient predominant trials (P<0.01). In subgroup analyses, SBP reductions were -9.3 mmHg (95% CI: -11.9, -6.6) vs. -4.9 mmHg (95% CI: -7.3, -2.5) 278

279	when pharmacotherapy was led by non-physician vs. physician (P<0.01), and -5.6
280	mmHg (95% Cl: -7.8, -3.3) vs9.3 mmHg (95% Cl: -13.1, -5.6) when SMS was
281	provided by nurses vs. pharmacists (P=0.01), respectively, all favoring TM-HTN
282	(Figures 3-4). Similarly, SBP reductions were -4.4 mmHg (95% CI: -6.6, -2.2) vs9.3
283	mmHg (95% CI: -11.4, -7.2) in non-White vs. White patient predominant trials (P<0.01),
284	respectively, favoring TM-HTN (Figure 5). There were no significant subgroup
285	differences by diabetes predominant trials (P=0.14). Both diabetes and non-White
286	patient predominant trials achieved -4.5 mmHg (95% CI: -5.9, -3.1) SBP reduction vs
287	9.6 mmHg (95% CI: -12.7, -6.4) in White patient predominant but not diabetes
288	predominant trials (P<0.01), favoring TM-HTN.
289	The pooled DBP difference was -2.7 mmHg (95% CI: -4.0, -1.5), favoring TM-
290	HTN intervention (Figure 2). In univariable meta-regression, the only variables
291	significantly associated with DBP difference were clinicians leading pharmacotherapy
292	and SMS, and race. DBP reduction was 2.8 mmHg more when pharmacotherapy was
293	led by non-physicians vs. physicians (P<0.01). Similarly, DBP reduction was 3.1 mmHg
294	more when SMS was provided by pharmacists vs. nurses (P=0.01). For every 10%
295	more non-White patients per trial, DBP reduction was 0.3 mmHg lower (P=0.04) or 2.7
296	mmHg lower DBP reduction in non-White vs. White patient predominant trials (P<0.01).
297	In subgroup analyses, DBP reductions were -4.0 mmHg (95% CI: -5.7, -2.3) vs1.1
298	(95% CI: -2.3, -0.04) when pharmacotherapy was led by non-physician vs. physician
299	(P<0.01), and -1.0 mmHg (95% CI: -2.1, 0.03) vs4.1 mmHg (95% CI: -6.4, -1.8) when
300	SMS was provided by nurses vs. pharmacists (P<0.01), respectively, all favoring TM-
301	HTN (Figures 3-4). Similarly, DBP reductions were -1.1 mmHg (95% CI: -2.3, -0.04) vs.

-4.0 mmHg (95% CI: -5.7, -2.3) in non-White vs. White patient predominant trials 302 (P<0.01), respectively, favoring TM-HTN (Figure 5). There were no significant subgroup 303 differences by diabetes predominant trials (P=0.20). Both diabetes and non-White 304 patient predominant trials achieved -0.9 mmHg (95% CI: -1.8, 0.06) DBP reduction vs. -305 4.2 mmHg (95% CI: -6.8, -1.6) in White patient predominant but not diabetes 306 predominant trials (P<0.01), favoring TM-HTN. 307 The mean pooled difference in BP control rate between TM-HTN intervention and 308 usual care was 10.1% (95% CI: 0.4, 19.9), favoring TM-HTN intervention (Figure 2). We 309 310 did not consider meta-regression and sub-group analysis for BP control due to only seven eligible trials. 311 To explore the differential effect of SMS on BP, in post-hoc analysis, we 312 313 conducted sub-group analysis according to whether SMS was well-developed or not. We did not find any significant difference for both SBP [-7.1 mmHg (95% CI: -10.4, -3.9) 314 vs. -8.5 mmHg (95% CI: -12.5, -4.5), (P=0.49)] and DBP [-2.0 mmHg (95% CI: -4.3, 0.4) 315 vs. -3.9 mmHg (95% CI: -5.9, -1.8), (P=0.10)] in trials with and without well-developed 316 SMS, respectively. 317 To further understand the differences seen by race, in post-hoc analysis, we 318 examined interaction of race with clinicians leading pharmacotherapy, SMS and 319 whether the SMS was well developed or not. We found that the only group achieving 320

lower BP reduction was non-White patient predominant trials (Supplement Table 6). Any

322 group with White patient predominant trials achieved higher BP reduction.

When limiting the analyses to the nine trials that used telemonitoring of SMBP, the pooled SBP and DBP differences were -7.8 mmHg (95% CI: -10.6, -5.0) and -3.0

mmHg (95% CI: -4.7, -1.2), respectively, favoring TM-HTN intervention (Figure 6), which 325 were not significantly different than the four trials without telemonitoring, SBP [-5.3 326 mmHg (95% CI: -9.6, -0.9), P=0.16] and DBP [-1.9 mmHg (95% CI: -3.9, 0.04), P=0.24], 327 328 respectively. TM-HTN trials using telemonitoring of SMBP were 13.9% (95% CI: 2.3, 25.5) more likely to control BP than usual care (Figure 6). In univariable meta-329 330 regression, the only variable significantly associated with SBP difference was race and for DBP difference was SMS (data not shown). Results from sub-group analyses were 331 similar to the main analyses (data not shown). 332

333

334 Discussion

To inform translation of TM-HTN in clinical practice in the US, we conducted a 335 systematic review and meta-analysis of US-based randomized trials. We found high 336 337 strength of evidence for TM-HTN trials lowering BP by 7.3/2.7 mmHg compared with usual clinic-based care, based on direct evidence, with mostly low study limitations and 338 without reporting bias (Supplement Table 5). Pharmacotherapy was more effective if 339 delivered by non-physicians (9.3/4.0 mmHg) than by physicians (4.9/1.1 mmHg), and 340 SMS was more effective when delivered by pharmacists (9.3/4.1 mmHq) than by nurses 341 (5.6/1.0 mmHg). Similarly, TM-HTN was more effective in reducing BP in trials primarily 342 enrolling White patients (9.3/4.0 mmHg) than non-White patients (4.4/1.1 mmHg). There 343 were no subgroup differences by diabetes patient predominant trials. Both diabetes and 344 345 non-White patient predominant trials achieved lower BP reduction (4.5/0.9 mmHg) than in White patient predominant but not diabetes predominant trials (9.5/4.2 mmHg). 346 Results were similar when limiting the analysis to trials using telemonitoring of SMBP. 347

Taken together, our study provides important insights for effective and equity-conscious TM-HTN implementation in the US (Figure 7).

Telemedicine is particularly appropriate for HTN management.² Obtaining 350 accurate and reliable BP is a basic requirement in HTN management. Yet accurate 351 clinic BP evaluation is challenging with limited assessment during sporadic and brief 352 clinic visits,⁴ which undermines clinicians confidence to escalate anti-hypertensive 353 medications.^{5,6} TM-HTN program integrates multiple home BP data, which enhances 354 clinicians' confidence to assess and manage HTN, and helps overcome clinical inertia.² 355 Enhancing patients' self-management skills is an important aspect of HTN care.⁷ Self-356 357 management comprises patients' knowledge about HTN, skills in medication adherence, lifestyle modifications, and chronic disease management.⁷ Effective SMS is 358 time consuming requiring ongoing and organized support.⁷ Brief and infrequent clinic 359 360 visit does not allow effective SMS. TM-HTN is an ongoing, team-based, HTN focused management approach allowing effective SMS.² Taken together, TM-HTN addresses 361 several shortcomings of the clinic-based HTN care. 362

Multilevel, multicomponent strategies, such as team-based care with medication 363 titration by non-physicians in clinic-based HTN management models are the most 364 effective approaches for BP control.¹¹⁻¹³ We found similar theme in the telemedicine 365 approach where non-physicians led pharmacotherapy was more effective than when 366 directly led by physicians. It is known that allowing non-physicians to offer 367 pharmacotherapy without needing routine approval from physicians will streamline 368 369 workflow, offer patient-centered collaborative care, and a focused algorithmic care by non-physicians encourages guideline concordant care while allowing physicians to 370

focus on complex cases. ³⁷ In practice, non-physicians providing pharmacotherapy in a
telemedicine program for a single condition is a matter of scalability, economy and
efficiency. We found similar theme for SMS by pharmacists vs. nurses. Future studies
should explore reasons for such difference. Adopting effective TM-HTN programs
requires considering these practical considerations and conducting local formative
assessment.

Our race pertinent analysis should be cautiously interpreted as the results could 377 be explained by other confounders. For example, we found more diabetes predominant 378 trials and well-developed SMS programs in non-White than White patient predominant 379 380 trials. Generally, a well-developed SMS intervention is focused on enhancing patient's 381 self-care skills. Conversely, an intervention without well-developed SMS program may have other focus (e.g., pharmacotherapy). Despite not noting significant BP differences 382 383 based on well-developed SMS intervention, confounding is still possible. We found no single non-White patient predominant trial that had non-physician leading 384 pharmacotherapy or pharmacists delivering SMS, which were both associated with the 385 highest improvement in BP. Nevertheless, racial differences were notable throughout 386 our analyses. It's possible that TM-HTN program implemented as such can exacerbate 387 inequities in HTN care in non-White patients. The attenuated BP difference in non-White 388 patient predominant trials (most of whom were Black patients) is likely because the 389 current TM-HTN programs were not designed and tailored to meet these patients' 390 needs.²³ For example, Black patients have reported several factors contributing to poor 391 BP control, including limited HTN knowledge, cultural factors, racism-related stress, 392 limited access to community resources and social determinants of health.³⁸⁻⁴⁰ Structural 393

factors contributing to racial disparities in telemedicine use for diabetes care has been 394 described previously.⁴¹ Accordingly, non-White patients will need proper support for 395 effective TM-HTN use.⁴² A barber shop-based, pharmacist managed HTN care 396 397 intervention was highly effective, supporting the importance of a contextually appropriate intervention.⁴³ To improve equity in HTN care, TM-HTN programs for non-398 White patients can adapt the intervention considering patient, clinician, and system-level 399 barriers.⁴² We found that both non-White patient and diabetes predominant trials 400 achieved smaller BP reduction than White patient predominant but not diabetes 401 predominant trials. The additional complexity to address diabetes in non-White 402 population perhaps add to the support needed for optimal use of SMBP. We did not find 403 variation in TM-HTN's effectiveness by patient's age, sex, education, diabetes status, 404 baseline BP, and TM-HTN intervention duration. 405

To our knowledge, this is the first meta-analysis limited to trials using SMBP-406 guided pharmacotherapy. There are several meta-analyses of trials conducted both in 407 and outside the US using SMBP with or without additional support.⁸⁻¹⁰ The additional 408 support was heterogeneous comprising either SMS only or SMBP-guided 409 pharmacotherapy only or both. SMBP alone can lead to some reductions in SBP (3-5 410 mmHg) and DBP (2-3 mmHg) at 6 months without difference at 12 months.^{8-10,44,45} 411 When SMBP is accompanied by co-interventions, like SMS, there can be moderate 412 reductions in BP and improved BP control at 12 months.⁹ The SBP difference of 7.3 413 mmHg seen in our study is comparable to 6.1 mmHg reduction seen in a meta-analysis 414 including trials from outside the US when SMBP was combined with intensive support.⁹ 415

Similarly, a prior meta-analysis found little heterogeneity of the benefit of SMBP across
 most HTN-related co-morbidities.²²

Although our study provides important insights into TM-HTN implementation, 418 there are other potential patient, clinician, and system level challenges in optimal use of 419 TM-HTN. For example, uptake of telemedicine intervention was 98% in an efficacy trial 420 of TM-HTN,²⁸ but in subsequent pragmatic trial with similar intervention, telemedicine 421 uptake was only 27%,⁴⁶ highlighting the practical challenges in TM-HTN 422 implementation.⁴⁷ Some patient related barriers in using TM-HTN intervention include 423 digital literacy, internet and smart phone access and sociocultural factors.^{42,44} A 2021 424 survey of nationally representative Americans 50-80 years of age showed that ~77% of 425 426 adults with HTN have home BP device with an arm cuff but only ~25% share their home BP readings with clinicians.⁴⁸ For effective use, patients should receive proper training 427 on SMBP and this training process should be integrated into the overall system of care.² 428 Another survey of primary care clinics showed that only 27.6% of clinics had written 429 policy to train patients in using SBMP and 48.8% designated a team member to provide 430 training to patients.⁴⁹ A pragmatic trial showed that only 38% of patients were able to 431 bring home BP diaries to clinicians, highlighting real-world challenges in using SMBP.⁵⁰ 432 Therefore, understanding and addressing barriers to SMBP and seamlessly transferring 433 home BP values to clinics are important for the success of TM-HTN implementation.^{44,50} 434 In this context, the results seen in our analysis limiting to trials that used telemonitoring 435 436 of SMBP, which was similar to the main results, should encourage adoption of telemonitoring of SMBP in contemporary TM-HTN programs. Telemonitoring facilitates 437 efficient SMBP communication with clinicians and can expedite clinical decisions.¹⁰ 438

Clinicians and system related relevant factors include availability of trained personnel to
provide SMS, acceptability and readiness among patients and clinicians in adopting a
new model of care and having a technical infrastructure to integrate home BP data into
electronic medical records. These factors should be explored in future studies.

We caution interpretation of our results considering the following potential limitations. 443 Despite our effort to reduce and address heterogeneity between trials during trials 444 selection and data analysis, some heterogeneity exists. Nevertheless, the confidence 445 interval of each individual trial's effect size overlapped the point estimate or the 446 confidence interval of the pooled effect, suggesting the plausibility of the variation in 447 effect size among trials.²¹ Our results, particularly the subgroup findings, imply 448 associations and not causations as limited number of eligible trials restricted 449 multivariable meta-regression modeling to address trial-level heterogeneity. One trial 450 451 had high risk of bias from missing data. Three additional trials had "some concern" for RoB from lack of pre-specified protocols as they were published when reporting 452 protocols were not routine. Although there was heterogeneity in the definition of BP 453 control across trials, the definition mostly reflected contemporary practice guidelines 454 suggesting appropriate practice standards in both intervention and control arms. There 455 were also minor differences in usual care across trials. Finally, non-White patient 456 457 predominant trials comprised of multiple races with Black race being majority. The attenuated BP effect noted could be related to the differences in the sociocultural 458 459 factors relevant for multiple races and ethnicities, which is important to consider when implementing TM-HTN intervention. 460

461

462 Conclusions

463	TM-HTN is more effective than clinic-based care for BP management in the US. The
464	benefit appears to be pronounced if pharmacotherapy is led by non-physician than
465	physicians and SMS is provided by clinical pharmacists than nurses, although the
466	reason for the latter should be first clarified in future studies. Trials enrolling majority
467	non-White patients seemed to achieve lower BP reduction than trials enrolling majority
468	White patients. As health systems plan to use TM-HTN programs in the US, locally
469	informed, patient-centered adaptation of TM-HTN is needed to provide equitable HTN
470	care.
471	
472	
473	Source of Funding

There was no funding associated with this study.

- 476 Abbreviations
- 477 BP: blood pressure
- 478 DBP: diastolic blood pressure
- 479 HTN: hypertension
- 480 RoB: risk of bias
- 481 SBP: systolic blood pressure

- 482 SMBP: self-measured blood pressure
- 483 SMS: self-management support

484 TM-HTN: telemedicine management of hypertension

- 485
- 486

487 **Conflict of Interest Disclosures**

488 Dr. Palakshappa's work on this project was supported by the National Heart, Lung, and

Blood Institute (NHLBI) of the National Institutes of Health under Award Number

490 K23HL146902. The funding organizations had no role in the design and conduct of the

491 study; collection, management, analysis, and interpretation of the data; preparation,

492 review, or approval of the manuscript; and decision to submit the manuscript for

493 publication. The content is solely the responsibility of the authors and does not

494 necessarily represent the official views of the National Institutes of Health.

495 Hayden Bosworth reports research funding through his institution from BeBetter

496 Therapeutics, Boehringer Ingelheim, Esperion, Improved Patient Outcomes, Merck,

497 NHLBI, Novo Nordisk, Otsuka, Sanofi, VA. Elton John Foundation, Hilton foundation,

498 Pfizer. He also provides consulting services for Abbott, Esperion, Imatar, Novartis,

499 Sanofi, Vidya, Walmart, Webmed. He was also on the board of directors of Preventric

500 Diagnostics.

501 Justin Moore provides consulting services for Medtronic.

502 All other authors had nothing substantial to disclose.

503 **REFERENCES**

- 1. Centers for Disease Control and Prevention. Facts About Hypertension. Centers for
- 505 Disease Control and Prevention. Accessed January 20, 2023. 2023. Available from
- 506 https://www.cdc.gov/bloodpressure/facts.htm
- 2. Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, Logan AG,
- 508 Magid DJ, Mckinstry B, Margolis KL et al. Evidence and Recommendations on the Use
- of Telemedicine for the Management of Arterial Hypertension. Hypertension.
- 510 2020;76(5):1368-1383. doi:10.1161/HYPERTENSIONAHA.120.15873
- 3. Ashman JJ, Rui P, Schappert SM, Strashny A. Characteristics of Visits to Primary
- 512 Care Physicians by Adults Diagnosed With Hypertension. Natl Health Stat Report. Sep
- 513 2017;(106):1-14. PMID: 29155688.
- 4. Powers BJ, Olsen MK , Smith VA, <u>Woolson</u> RF, <u>Bosworth</u> HB, <u>Oddone</u> EZ.
- 515 Measuring Blood Pressure for Decision Making and Quality Reporting: Where and How
- 516 Many Measures? Annals of Internal Medicine. 2011;154(12):781-788.
- 517 doi:10.7326/0003-4819-154-12-201106210-00005 %m 21690592
- 518 5. Crowley MJ, Smith VA, Olsen MK, <u>Danus</u> S, <u>Oddone</u> EZ, <u>Bosworth</u> HB, <u>Powers</u> BJ.
- 519 Treatment intensification in a hypertension telemanagement trial: clinical inertia or good
- clinical judgment? Hypertension. Oct 2011;58(4):552-8.
- 521 doi:10.1161/hypertensionaha.111.174367
- 522 6. Patil SJ, Wareg NK, Hodges KL, <u>Smith</u> JB, <u>Kaiser</u> MS, <u>LeFevre</u> ML. Home Blood
- 523 Pressure Monitoring in Cases of Clinical Uncertainty to Differentiate Appropriate

- Inaction From Therapeutic Inertia. Ann Fam Med. 2020;18(1):50-58.
- 525 doi:10.1370/afm.2491
- 526 7. Centers for Disease Control and Prevention. Best Practices for Heart Disease and
- 527 Stroke: A Guide to Effective Approaches and Strategies. Centers for Disease Control
- and Prevention. Accessed January 21, 2023. 2023. Available from
- 529 https://www.cdc.gov/dhdsp/pubs/guides/best-practices/index.htm
- 530 8. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring
- in the management of hypertension: a systematic review and meta-analysis. Ann Intern
- 532 Med. Aug 6 2013;159(3):185-94. doi:10.7326/0003-4819-159-3-201308060-00008
- 533 9. Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, Earle K,
- 534 George J, Godwin M, Green BB et al. Self-monitoring of blood pressure in hypertension:
- 535 A systematic review and individual patient data meta-analysis. PLoS Med. Sep
- 536 2017;14(9):e1002389. doi:10.1371/journal.pmed.1002389
- 10. Agarwal R, Bills JE, Hecht TJW, Light RP. Role of Home Blood Pressure Monitoring
- in Overcoming Therapeutic Inertia and Improving Hypertension Control. Hypertension.
- 539 2011;57(1):29-38. doi:10.1161/HYPERTENSIONAHA.110.160911
- 11. Walsh JME, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, Owens
- 541 DK, Goldstein MK. Quality Improvement Strategies for Hypertension Management: A
- 542 Systematic Review. Medical Care. 2006;44(7):646-657.
- 543 doi:10.1097/01.mlr.0000220260.30768.32

- 12. Mills KT, Obst KM, Shen W, Molina S, Zhang HJ, He H, Cooper LA, He J.
- 545 Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in
- 546 Hypertensive Patients: A Systematic Review and Meta-analysis. Ann Intern Med. Jan
- 547 16 2018;168(2):110-120. doi:10.7326/m17-1805
- 13. Proia KK, Thota AB, Njie GJ, Finnie RKC, Hopkins DP, Mukhtar Q, Pronk NP,
- 549 Zeigler D, Kottke TE, Rask KJ et al. Team-based care and improved blood pressure
- 550 control: a community guide systematic review. American journal of preventive medicine.
- 551 Jul 2014;47(1):86-99. doi:10.1016/j.amepre.2014.03.004
- 14. The SPRINT Research Group. Final Report of a Trial of Intensive versus Standard
- 553 Blood-Pressure Control. New England Journal of Medicine. 2021;384(20):1921-1930.
- 554 doi:10.1056/NEJMoa1901281.
- 15. Giustini D, Acharya S, Neupane G, Pokharel Y. Assessing Heterogeneity of
- 556 Hypertension Treatment Using Telemedicine and Home Blood Pressure Monitoring by
- 557 Provider Types: A Systematic Review and Meta-Analysis of US Clinical Trials [Internet].
- 558 Accessed July 23, 2023, 2023. DOI: 10.17605/OSF.IO/NHMB4
- 16. Catalyst NEJM. What Is Telehealth? Catalyst Carryover. 2018;4(1). doi:10.1056/CA
- 560 T.18.0268
- 561 17. Centers for Disease Control and Prevention. Telehealth and Telemedicine: A
- 562 Research Anthology of Law and Policy Resources. Centers for Disease Control and
- 563 Prevention. Accessed June 26, 2023. 2023. Available from: https://
- 564 www.cdc.gov/phlp/publications/topic/anthologies/anthologies-telehealth.html.

- 18. Glanville J, Kotas E, Featherstone R, Dooley G. Which are the most sensitive
- search filters to identify randomized controlled trials in MEDLINE? J Med Libr Assoc.
- 567 Oct 1 2020;108(4):556-563. doi:10.5195/jmla.2020.912
- 19. Cheung A, Popoff E, Szabo SM. Application of text mining to the development and
- validation of a geographic search filter to facilitate evidence retrieval in Ovid MEDLINE:
- An example from the United States. Health Info Libr J. Dec 21 2022;
- 571 doi:10.1111/hir.12471
- 20. Higgins JPT Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk
- of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T,
- 574 Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of
- 575 Interventions version 6.3 (updated February 2022). Cochrane 2022. Accessed January
- 1, 2023. 2022. Available from https://training.cochrane.org/handbook/current/chapter-08
- 577 21. Berkman ND, Lohr KN, Ansari M, Balk EM, Kane R, McDonagh M, Morton
- 578 SC, Viswanathan M, Bass EB, Butler M et al. Grading the strength of a body of
- 579 evidence when assessing health care interventions: an EPC update. J Clin Epidemiol.
- 580 2015 Nov;68(11):1312-24. doi: 10.1016/j.jclinepi.2014.11.023. Epub 2014 Dec 20.
- 581 PMID: 25721570.
- 582 22. Sheppard JP, Tucker KL, Davison WJ, <u>Stevens</u> R, <u>Aekplakorn</u> W, <u>Bosworth</u>
- 583 HB, <u>Bove</u> A, <u>Earle</u> K, <u>Godwin</u> M, <u>Green</u> BB et al. Self-monitoring of Blood Pressure in
- 584 Patients With Hypertension-Related Multi-morbidity: Systematic Review and Individual
- 585 Patient Data Meta-analysis. Am J Hypertens. Mar 13 2020;33(3):243-251.
- 586 doi:10.1093/ajh/hpz182

- 23. Feldman PH, McDonald MV, Barrón Y, Gerber LM, Peng TR. Home-based
- interventions for black patients with uncontrolled hypertension: a cluster randomized
- controlled trial. Journal of comparative effectiveness research. Mar 2016;5(2):155-68.
- 590 doi:10.2217/cer.15.60
- 591 24. Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, Gentry
- 592 PW, Rose C, Houtven CV, Wang V et al. Home Blood Pressure Management and
- ⁵⁹³ Improved Blood Pressure Control: Results From a Randomized Controlled Trial.
- 594 Archives of Internal Medicine. 2011;171(13):1173-1180.
- 595 doi:10.1001/archinternmed.2011.276
- 596 25. Hebert PL, Sisk JE, Tuzzio L, Casabianca JM, Pogue VA, Wang JJ, Chen Y,
- 597 Cowles C, McLaughlin MA. Nurse-led disease management for hypertension control in
- ⁵⁹⁸ a diverse urban community: a randomized trial. Journal of general internal medicine.

Jun 2012;27(6):630-9. doi:10.1007/s11606-011-1924-1

- 26. Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, Carrell D, Tyll L,
- Larson EB, Thompson RS. Effectiveness of Home Blood Pressure Monitoring, Web
- 602 Communication, and Pharmacist Care on Hypertension Control: A Randomized
- 603 Controlled Trial. JAMA. 2008;299(24):2857-2867. doi:10.1001/jama.299.24.2857
- 27. Wakefield BJ, Holman JE, Ray A, <u>Scherubel M, Adams MR, Hillis SL, Rosenthal</u>
- 605 GE. Effectiveness of home telehealth in comorbid diabetes and hypertension: a
- randomized, controlled trial. Telemed J E Health. May 2011;17(4):254-61.
- 607 doi:10.1089/tmj.2010.0176

- 28. Margolis KL, Asche SE, Bergdall AR, <u>Dehmer</u> SP, <u>Groen</u> SE, <u>Kadrmas</u> HM, <u>Kerby</u>
- 609 TJ, Klotzle KJ, Maciosek MV, Michels RD et al. Effect of home blood pressure
- telemonitoring and pharmacist management on blood pressure control: a cluster
- randomized clinical trial. Jama. Jul 3 2013;310(1):46-56. doi:10.1001/jama.2013.6549
- 29. Rudd P, Miller NH, Kaufman J, <u>Kraemer</u> HC, <u>Bandura</u> A, <u>Greenwald</u> G, <u>Debusk</u> RF.
- Nurse management for hypertension. A systems approach. Am J Hypertens. Oct
- 614 2004;17(10):921-7. doi:10.1016/j.amjhyper.2004.06.006
- 30. Artinian NT, Flack JM, Nordstrom CK, <u>Hockman</u> EM, <u>Washington</u> OGM, <u>Jen</u>
- 616 KLC, Fathy M. Effects of Nurse-Managed Telemonitoring on Blood Pressure at 12-
- Month Follow-Up Among Urban African Americans. Nursing Research. 2007;56(5):312-
- 618 322. doi:10.1097/01.NNR.0000289501.45284.6e
- 31. Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE, Kroner BA. A pharmacist-
- led, American Heart Association Heart360 Web-enabled home blood pressure
- monitoring program. Circ Cardiovasc Qual Outcomes. Mar 1 2013;6(2):157-63.
- 622 doi:10.1161/circoutcomes.112.968172
- 32. Magid DJ, Ho PM, Olson KL, <u>Brand</u> DW, <u>Welch</u> LK, <u>Snow</u> KE, <u>Lambert-Kerzner</u>
- 624 AC, <u>Plomondon</u> ME, <u>Havranek</u> EP. A multimodal blood pressure control intervention in
- 3 healthcare systems. The American journal of managed care. Apr 2011;17(4):e96-103.
- 626 PMID: 21774100
- 33. Soghikian K, Casper SM, Fireman BH, <u>Hunkeler</u> EM, <u>Hurley</u> LB, <u>Tekawa</u> IS, <u>Vogt</u>
- TM. Home Blood Pressure Monitoring: Effect on Use of Medical Services and Medical
- 629 Care Costs. Medical Care. 1992;30(9):855–865. PMID: 1518317

- 34. Chandler J, Sox L, Kellam K, Feder L, Nemeth L, Treiber F. Impact of a Culturally
- Tailored mHealth Medication Regimen Self-Management Program upon Blood Pressure
- among Hypertensive Hispanic Adults. Int J Environ Res Public Health. 2019;16(7).
- 633 doi: <u>10.3390/ijerph16071226</u>
- 35. Bove AA, Homko CJ, Santamore WP, Kashem M, Kerper M, Elliott DJ. Managing
- 635 hypertension in urban underserved subjects using telemedicine—A clinical trial.
- American Heart Journal. 2013;165(4):615-21. Available from
- 637 <u>https://doi.org/10.1016/j.ahj.2013.01.004</u>
- 36. Deeks JJ Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and
- undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T,
- 640 Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of
- Interventions version 6.3 (updated February 2022). Cochrane, 2022. Accessed January
- 1, 2022. Available from https://training.cochrane.org/handbook/current/chapter-10
- ⁶⁴³ 37. Carter BL, Rogers M, Daly J, Zheng S, James PA. The potency of team-based care
- 644 interventions for hypertension: a meta-analysis. Arch Intern Med. Oct 26
- 645 2009;169(19):1748-55. doi:10.1001/archinternmed.2009.316
- 38. Flynn SJ, Ameling JM, Hill-Briggs F, Wolff JL, Bone LR, Levine DM, Roter
- 647 DL, Lewis-Boyer L, Fisher AR, Purnell L et al. Facilitators and barriers to hypertension
- self-management in urban African Americans: perspectives of patients and family
- members. Patient Prefer Adherence. 2013;7:741-9. doi:10.2147/ppa.S46517
- 39. Milani RV, Price-Haywood EG, Burton JH, Wilt J, Entwisle J, Lavie CJ. Racial
- Differences and Social Determinants of Health in Achieving Hypertension Control. Mayo

652 Clinic Proceedings. 2022/08/01/ 2022;97(8):1462-1471. doi:

- 653 https://doi.org/10.1016/j.mayocp.2022.01.035
- 40. Woods SB, Hiefner AR, Udezi V, Slaughter G, Moore R, Arnold EM. 'They should
- walk with you': the perspectives of African Americans living with hypertension and their
- family members on disease self-management. Ethn Health. Feb 28 2022:1-26.
- 657 doi:10.1080/13557858.2022.2040958
- 41. Trief PM, Izquierdo R, Eimicke JP, Teresi JA, Goland R, Palmas W, Shea
- 659 S, Weinstock RS. Adherence to diabetes self care for white, African-American and
- 660 Hispanic American telemedicine participants: 5 year results from the IDEATel project.
- 661 Ethnicity & Health. 2013/02/01 2013;18(1):83-96. doi:10.1080/13557858.2012.700915
- 42. Bailey JE, Gurgol C, Pan E, Njie S, Emmett S, Gatwood J, Gauthier L, Rosas LG,
- 663 Kearney SM, Robler SK et al. Early Patient-Centered Outcomes Research Experience
- 664 With the Use of Telehealth to Address Disparities: Scoping Review. J Med Internet Res.
- 665 2021/12/7 2021;23(12):e28503. doi:10.2196/28503
- 43. Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, Brettler J, Rashid M,
- 667 Hsu B, Foxx-Drew D et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in
- Black Barbershops. New England Journal of Medicine. 2018;378(14):1291-1301.
- 669 doi:10.1056/NEJMoa1717250
- 44. Shimbo D, Artinian NT, Basile JN, Krakoff LR, Margolis KL, Rakotz MK, Wozniak G,
- 671 American Heart Association and American Medical Association. Self-Measured Blood
- 672 Pressure Monitoring at Home: A Joint Policy Statement From the American Heart

- 673 Association and American Medical Association. Circulation. Jul 28 2020;142(4):e42-
- e63. doi:10.1161/cir.000000000000803
- 45. Reboussin DM, Allen NB, Griswold ME, <u>Guallar</u> E, <u>Hong</u> Y, <u>Lackland</u> DT, <u>MillerIII</u>
- 676 ER
- 677 Polonsky T, Thompson-Paul AM, Vupputuri S et al. Systematic Review for the 2017
- 678 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the
- 679 Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults:
- 680 A Report of the American College of Cardiology/American Heart Association Task Force
- on Clinical Practice Guidelines. Circulation. 2018;138(17):e595-e616.
- 682 doi:10.1161/CIR.00000000000000000
- 46. Margolis KL, Bergdall AR, Crain AL, JaKa MM, Anderson JP, Solberg LI, Sperl-
- ⁶⁸⁴ <u>Hillen</u> J, <u>Beran</u> M, <u>Green</u> BB, <u>Haugen</u> P et al. Comparing Pharmacist-Led Telehealth
- 685 Care and Clinic-Based Care for Uncontrolled High Blood Pressure: The Hyperlink 3
- 686 Pragmatic Cluster-Randomized Trial. Hypertension. 2022;79(12):2708-2720.
- 687 doi:10.1161/HYPERTENSIONAHA.122.19816
- 47. Margolis KL, Crain AL, Green BB, O'Connor PJ, Solberg LI, Beran M, Bergdall
- 689 AR, Pawloski PA, Ziegenfuss JY, JaKa MM et al. Comparison of explanatory and
- 690 pragmatic design choices in a cluster-randomized hypertension trial: effects on
- enrollment, participant characteristics, and adherence. BMC. 2022; doi:
- 692 <u>10.1186/s13063-022-06611-3</u>
- 48. Springer MV, Malani P, Solway E, Kirch M, Singer DC, Kullgren JT, Levine DA.
- 694 Prevalence and Frequency of Self-measured Blood Pressure Monitoring in US Adults

- 695 Aged 50-80 Years. JAMA Network Open. 2022;5(9):e2231772-e2231772.
- 696 doi:10.1001/jamanetworkopen.2022.31772
- 49. Woolsey S, Brown B, Ralls B, Friedrichs M, Stults B. Diagnosing Hypertension in
- 698 Primary Care Clinics According to Current Guidelines. The Journal of the American
- 699 Board of Family Medicine. 2017;30(2):170-177. doi:10.3122/jabfm.2017.02.160111
- 50. Ogedegbe G, Tobin JN, Fernandez S, Cassells A, Diaz-Gloster M, Khalida
- C, <u>Pickering</u> T, <u>Schwartz</u> JE. Counseling African Americans to Control Hypertension:
- cluster-randomized clinical trial main effects. Circulation. May 20 2014;129(20):2044-51.
- 703 doi:10.1161/circulationaha.113.006650

704

714 List of table

715 Table 1. Key features of included trials

	Mea n		Major ity		≤High school	Baselin e SBP/D		Well- develo ped	TM- HTN durati	BP Control definition (mmHg)		
Study, publicat ion year	age (year s)	Wo men (%)	White	Major ity DM	Educati on (%)	BP (mmHg)	Pharmacoth erapy/SMS provider	ŚМS	on (mont hs)		Primary Outcom e	Region
Chandle r et al,	10.5	00.0	N	Missi	74 5	151.5/8	Physician/ Automated	Yes	6	<140/90	∆SBP at 6	Charlest
2019	46.5	66.3	No	ng	71.5	5.7	app-based	No	6	<140/90 or	months BP	on, SC
Magid et al, 2013	59.6	39.6	Yes	Yes	NA	147.1/8 8.8	Pharmacist/ pharmacist	No	0	<130/80 (with DM)	control at 6 months	Denver, CO
Wakefiel d et al, 2011	68	2	Yes	Yes	47	136/mis sing	Physician/	Yes	6	Missing	∆SBP and HbA1C at 6 months	lowa City, IA
Margolis et al, 2013	61.1	45	Yes	No	17	148/85	nurse Pharmacist/ pharmacist	No	12	<140/90 or <130/80 (with DM or CKD)	BP control at 12 months	St. Paul, MN
Green et al, 2008	59.1	52.2	Yes	Missi	8	151.9/8 9.1	Pharmacist/ pharmacist	Yes	12	<140/90	ΔBP and BP control at 12 months	WA and ID
Rudd et al, 2004	59.5	53	Yes	No	23	Missing	Nurse/nurse	No	6	Missing	∆SBP and DBP at 6 months	Stanford , Mountai n view, CA
Hebert et al, 2011	60.8	70.9	No	Yes	81.2	153/86	Physician/ nurse	Yes	9	<140/90 or <130/80 (with DM or renal disease)	∆SBP at 9 months	New York, NY
Magid et al, 2011	65.9	35.3	Yes	Yes	22.9	147.1/8 7.3	Pharmacist/ pharmacist	No	6	<140/90 or <130/80 (with DM or CKD)	ΔSBP and DBP at 6 months	Denver, CO
Boswort h et al, 2011	64	8	No	Yes	13	129/77	Physician/ nurse	Yes	18	<140/90 or <130/80 (with DM)	BP control at 18 months	Durham, NC
Bove et	50.0	05.4			40.0	155.2/8	Physician/Nu	No	6	<140/90	SBP control at 6	Philadel phia, PA and Wilmingt
al 2013 Artinian et al,	59.6	65.1	No	Yes	46.9	8,3 156.3/8	rse Physician/	Yes	12	<135/85	months ∆SBP and DBP at 12	on, DE Detroit,
2007	59.6	64.3	No	Yes	59.2	8.9	nurse	NA	12	<140/90	months Cost for ∆SBP	MI
Soghikia n et al, 1992	54.2	50.2	No	NA	28.1	138.8/8 6.2	Physician/NA				and DBP at 12 months	San Francisc o, CA
Feldman et al,	64.3	66	No	Yes	40	156/87	Physician/nur se	Yes	12	BP <140/90 or <130/80	BP control	New York, NY

2016					(with DM or	at 12	
2010						months	
						montina	

716

- Abbreviations: BP = blood pressure; CKD = chronic kidney disease; DBP = diastolic
- ⁷¹⁸ blood pressure; DM = diabetes mellitus; HbA1c: glycated hemoglobin; NA = not
- applicable; SBP = systolic blood pressure; SMS = self-management support; TM-HTN =
- telemedicine management of hypertension; Δ means difference.

721

- 722 White patient predominant trials enrolled >50% patients/trial, and diabetes predominant
- trials enrolled \geq 25% patients with diabetes/trial.
- Magid et al, 2013 and Magid et al, 2011 studies reported DM or CKD together, which
- we considered as the presence of DM for our analyses.

Usual care in all trials comprised clinic based HTN management without a telemedicine

- program so that pharmacotherapy was not guided by home BP values. Margolis et al,
- study additionally referred usual care participants to a medication therapy management
- pharmacist for consultation (1-2 visits without telephone follow-up or prolonged
- monitoring). Chandler et al, study provided text messages of healthy lifestyle support to

731 usual care patients.

Feldman et al, Hebert et al, Chandler et al and Artinian et al included 100% non-White


733 patients.

- The intervention was leveraged via community and not via clinic in Feldman et al and
- 735 Artinian et al. Patients' physician received BP data to guide pharmacotherapy.

- 736 Margolis et al, and Feldman et al were cluster randomized trials and the rest
- randomized individual participants. Margolis et al used clinic as a cluster and Feldman
- et al study used home care nurse as a cluster.
- BP assessment for the outcome used research BP measured in clinic for all studies
- except for Feldman et al (home BP measured by nurse) and Artinian et al (research
- staff measured BP at community centers).

755 List of Figures

756 Figure 1. PRISMA flow diagram of search results and eligible articles



758 Abbreviations: BP = blood pressure; DBP = diastolic blood pressure; HTN =


759 hypertension; SBP = systolic blood pressure; US = United States

760

757

761

763 Figure 2: Mean overall pooled difference in SBP, DBP and BP control rate




Abbreviations: BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic

766 blood pressure.

- $l^2 > 60\%$ (P<0.05) is considered significantly heterogeneous according to the Cochrane
- 768 Handbook for Systematic Reviews.


778 Figure 3: Mean BP difference according to clinicians leading pharmacotherapy



Abbreviations: BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic

781 blood pressure.

788 Figure 4: Mean BP difference according to clinicians providing SMS




Abbreviations: BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic

⁷⁹¹ blood pressure; SMS = self-management support.

799 Figure 5: Mean BP difference between majority Non-White vs. White patient


800 predominant trials



Abbreviations: BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic

⁸⁰³ blood pressure.


811 Figure 6: Overall BP outcomes in studies using tele monitoring of SMBP



- Abbreviations: BP = blood pressure; DBP = diastolic blood pressure; SBP = systolic
- blood pressure; SMBP = self-measured blood pressure.


815

816 Figure 7. Univariable regression forest plot



818 Abbreviations: DBP = diastolic blood pressure; HTN = hypertension; mmHg = millimeter

of mercury; SBP = systolic blood pressure; SMS = self-management support; TM-HTN



821	More negative BP values reflect greater BP reduction with TM-HTN compared with
822	usual care.
823	
824	
825	
826	
827	
828	